MDS Hub attends three key conferences in Q4 ensuring the MDS Community receive the latest news in myelodysplastic syndromes

Press release: Available for immediate release

The MDS Hub, run by Scientific Education Support (SES) in partnership with the European LeukemiaNet (ELN), is an open-access online resource dedicated to providing balanced, reliable, and up-to-date medical education in myelodysplastic syndromes (MDS). In Q4, the MDS Hub has continued to provide up-to-date coverage of research in MDS, including topics most relevant for the medical field.

This quarter, the hub virtually attended the Lymphoma, Leukemia, and Myeloma congress on October 18–22, and provided live social media coverage of key talks on the latest in treatment and prognosis for MDS.

The MDS Hub also produced live social media coverage of the 6th International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM 2021) on October 21–24. This was another great opportunity to summarize data presented from experts on topics related to transplantation and novel agents.

In November, the MDS Hub held a steering committee meeting, where we gathered valued expertise from our steering committee members on unmet needs to cover in MDS. We will use this information to guide our content output, including key topics to prioritize in future conferences.

On December 8–14, we attended the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition. We provided both virtual and in-person coverage on a large number of talks. A downloadable resource of the top abstracts to look out for in MDS can be found here.

Reviewing the MDS Hub’s impact this quarter, Mia Hill, IME Director at Scientific Education Support, said:

“The MDS Hub has continued to expand its outreach in Q4, and virtual attendance of the key conferences for MDS has been of great importance. We have seen increased interaction on social media, with over 100 new followers on Twitter and just under 30,000 impressions from our daily posts, which included congress updates and article links. We expect further growth before the end of the year as our extensive coverage of ASH 2021 continues.”

We would like to take this opportunity to show our gratitude for our existing supporters—Novartis (Silver), Bristol Myers Squibb (Bronze), Geron Corporation (Contributor), and Takeda (Contributor).

For more information on the MDS Hub, please visit mds-hub.com.

For media enquiries, or to explore collaboration opportunities, please contact or syndromes (MDS) refer to a group of hematopoietic disorders that result in the production of insufficient numbers of healthy blood cells, along with changes in bone marrow morphology and, eventually, overall failure of the bone marrow. Progression of MDS can be indolent or aggressive, and some patients may go on to develop acute myeloid leukemia.

The MDS Hub is an open-access online resource, dedicated to providing balanced, credible, and up-to-date medical education in MDS. Our aim is to enhance knowledge of MDS through the multichannel dissemination of global advances related to their classification, diagnosis, treatment, and management.

The MDS Hub shares new data, evidence-based articles, therapy approvals, expert opinions, and international congress coverage to treatment teams and researchers around the world. Informed by patients, curated by world leaders, and endorsed by expert societies, the MDS Hub supports HCPs worldwide.

Founded in partnership with the European LeukemiaNet (ELN) in 2020, the MDS Hub is guided by an international steering committee of experts in the field of MDS. The steering committee meet regularly to discuss the performance of the MDS Hub and to devise action plans on how best to support the MDS community and address any unmet educational needs.

Funding for our hubs is made possible through financial support from the pharmaceutical industry. All content is developed by SES in collaboration with an expert steering committee. All content is independent, and the educational supporters are allowed no influence on the content.

If you are interested in becoming an MDS Hub supporter, please contact is a medical education company with projects such as community physician education though our therapy hubs, community awareness and education through our ‘Know’ education initiatives, and academic researcher education through Entrepreneurs in Clinical Academia (ECA) programs.

Scientific Education Support already has a portfolio of successful websites supporting the advancement of medical education in the field of hemato-oncology: the ALL Hub, AML Hub, GvHD Hub, Lymphoma Hub, Multiple Myeloma Hub, and MPN Hub.

220 participating centers in 44 countries with more than 1000 researchers and clinicians are cooperating in the European LeukemiaNet. The objective is to integrate the about 120 leading leukemia trial groups (CML, AML, ALL, CLL, MDS, MPN), their interdisciplinary partner groups (diagnostics, treatment research, registry, guidelines), industry and SMEs across Europe to form a network promoting cooperative research for curing leukemia.